Abbisko Cayman Limited
和譽開曼有限責任公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2256)

VOLUNTARY ANNOUNCEMENT
ABBISKO THERAPEUTICS DELIVERED ORAL PRESENTATION OF PRELIMINARY FIRST-IN-HUMAN TRIAL RESULTS OF ITS HIGHLY SELECTIVE FGFR2/3 INHIBITOR ABSK061 AT THE 2024 ESMO TAT

Abbisko Cayman Limited (the "**Company**", together with its subsidiaries, the "**Group**") hereby informs the shareholders and potential investors of the Company of the attached press release that Abbisko Therapeutics Co., Ltd.("**Abbisko Therapeutics**"), a subsidiary of the Company, orally presented the first-in-human data of its next-generation highly selective FGFR2/3 inhibitor ABSK061 during the 2024 European Society for Medical Oncology Targeted Anticancer Therapies Congress ("**ESMO TAT**").

This is a voluntary announcement made by the Company. The Group cannot guarantee that ABSK061 will ultimately be successfully marketed. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Abbisko Cayman Limited
Dr. Xu Yao-Chang
Chairman of the Board

Shanghai, 28 February 2024

As at the date of this announcement, the board of directors of the Company comprises Dr. Xu Yao-Chang, Dr. Yu Hongping and Dr. Chen Zhui as executive directors; Ms. Tang Yanmin as non-executive director; and Dr. Sun Piaoyang, Mr. Sun Hongbin and Mr. Wang Lei as independent non-executive directors.

Abbisko Therapeutics Delivered Oral Presentation of Preliminary First-in-Human Trial Results of Its Highly Selective FGFR2/3 Inhibitor ABSK061 at the 2024 ESMO TAT

On 28 February 2024, Abbisko Therapeutics orally presented the first-in-human data of its next-generation highly selective FGFR2/3 inhibitor ABSK061 during the 2024 ESMO TAT. The ESMO TAT was held in Paris, France from 26 February 2024 to 28 February 2024.

As the first selective FGFR2/3 inhibitor entering clinical trial globally, ABSK061 demonstrated lower hyperphosphatemia and other AEs compared to prior pan-FGFR inhibitors in dose-escalation trials for patients with advanced solid tumors. Multiple FGFR2/3-altered patients, including lung, gastric and other cancer types, showed responses to ABSK061 treatment. These results also pave the road for future development of ABSK061 for treating achondroplasia and other diseases.

ABSK061 presented the followings at the ESMO TAT:

Title: First-in-human Study of ABSK061, A Selective Fibroblast Growth Factor Receptor (FGFR) 2/3 Inhibitor for Treating Patients with Advanced Solid Tumors

- Abstract: 450
- Lecture Time: 26 February 2024; 16:37 – 16:45 CET
- Category: advanced/metastatic solid tumors
- Key points:

  This study is a global multi-center, open-label Phase I trial designed to evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of the FGFR2/3 inhibitor ABSK061 in patients with advanced solid tumors.

  As of December 2023, a total of 29 patients were enrolled in the Phase Ia dose-escalation cohort, with a median age of 54 years old. The escalation began with an initial dose of 5mg BID and included 8 dose levels in total. No Dose Limiting Toxicity (DLT) events were observed in dose-escalation part, and two dose cohorts, 75mg BID and 150mg QD, advanced to the Recommended Dose for Expansion ("**RDE**") confirmation phase. The RDE confirmation cohorts are actively enrolling patients with FGFR-activating alterations to further confirm the efficacy.

  Efficacy: Among 8 patients with solid tumors carrying FGFR-activating alterations (FGFR2 Fusion/Amplification or FGFR3 Fusion), as of the time of publication, 3 patients achieved confirmed partial response (cPR), resulting in an Objective Response Rate (ORR) of 37.5%; 3 patients achieved Stable Disease (SD), and 2 patients experienced Disease Progression (PD). The Disease Control Rate (DCR) was 75%.

  Safety: Differentiated safety profile indicates high selectivity of FGFR2/3 inhibition. Most AEs are low grade and essentially reversible. Compared to pan-FGFR inhibitors, the incidence of hyperphosphatemia and diarrhea is lower, and the severity is reduced.

Conclusion: As the first highly selective FGFR2/3 inhibitor entering clinical trial, ABSK061 has demonstrated promising efficacy during the dose-escalation phase, along with differentiated and tolerable safety profile compared to pan-FGFR inhibitors. These positive findings warrant further investigation.

About Abbisko Therapeutics

Founded in April 2016, Abbisko Therapeutics Co., Ltd., a subsidiary of Abbisko Cayman Limited (Stock Code on the Hong Kong Stock Exchange: 2256.HK), is an oncology-focused biopharmaceutical company founded in Shanghai, dedicated to discovering and developing innovative medicines to treat unmet medical needs in China and globally. The Company was established by a group of seasoned drug hunters with rich R&D and managerial expertise from top multinational pharmaceutical companies. Since its founding, Abbisko Therapeutics has built an extensive pipeline of 16 innovative small molecule programs focused on precision oncology and immuno-oncology, including eight clinical stage assets.

Please visit www.abbisko.com for more information.

Forward-Looking Statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.